Glycogen Synthase Kinase 3: A Point of Integration in Alzheimer’s Disease and a Therapeutic Target?

Siddhartha Mondragón-Rodríguez,1 George Perry,2,3 Xiongwei Zhu,3 Paula I. Moreira,4,5 and Sylvain Williams1

1 Department of Psychiatry, Douglas Hospital Research Center, McGill University, Montreal, QC, Canada H4H 1R3
2 UTSA Neurosciences Institute and Department of Biology, College of Sciences, The University of Texas at San Antonio, San Antonio, TX, USA
3 Department of Pathology, Case Western Reserve University, Cleveland, OH, USA
4 Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
5 Faculty of Medicine, Institute of Physiology, University of Coimbra, Coimbra, Portugal

Correspondence should be addressed to Siddhartha Mondragón-Rodríguez, sidmonrod@gmail.com

Received 7 February 2012; Revised 20 April 2012; Accepted 3 May 2012

1. Introduction

Glycogen synthase kinase 3 (GSK3) is an evolutionarily conserved protein that is active in resting cells and is inhibited in response to activation of several distinct pathways such as the Wnt, insulin, and the growth factor pathway [1–7]. GSK3 activity is regulated by different mechanisms, including (a) phosphorylation at an N-terminal serine [7, 8], (b) through phosphorylation of a tyrosine residue [9], (c) through phosphorylation of a C-terminal serine residue [10], and (d) through disruption of the axin-β-catenin multiprotein complex [4, 11, 12]. The other requirement of GSK3 is that most of its substrates require prior phosphorylation at residue 4 or 5 amino acids C-terminal to the target residue [13].

GSK3 has two isoforms GSK3α and GSK3β, which are encoded by different genes [14]. In mouse, rat, and human, an alternative isoform (GSK3β2) that contains a 13-amino-acid insert near the catalytic domain was reported [15]. In opposition to GSK3α and GSK3β, GSK3β2 is specifically found in the nervous system and has been strongly linked to neurodevelopment [15].

In order to participate in all these events, GSK3 has a broad range of substrates: cyclic AMP response element-binding protein (CREB), neurogenin 2, SMAD1, NFKappaB, Myc, heat shock factor-1, cyclin D1, nuclear factor of activated T-cells and CCAAT/enhancer-binding proteins, c-Jun, β-catenin, and microtubule-associated proteins like MAP2 and tau [16–18]. GSK3 regulates some of these factors by controlling their protein levels. However, changes in GSK3 activity have been associated with neurodegenerative diseases, such as bipolar disorder, schizophrenia, and Alzheimer’s disease (AD) [19]. Indeed, in AD the active form of GSK3β was found to be directly related to the hyperphosphorylation of tau present in paired helical filament (PHF)-tau of neurofibrillary tangles (NFTs) [20]. Importantly and due to the fact that most drugs bind and compete with ATP, there appears to be only a single amino acid difference (Glu196 in GSK3α, Asp133 in GSK3β) making it difficult to identify an inhibitor that can distinguish the two isoforms.
Overall, it is clear that GSK3 is related to AD development, and, more importantly, current data suggest that both isoforms (GSK3α and GSK3β) contribute to AD pathogenesis.

2. Tau Pathology and GSK3

Tau is an axonal protein that regulates microtubule stability [21]; however, during AD tau is abnormally phosphorylated and aggregates into NFTs [22, 23]. Tau has at least 45 phosphorylation sites, mostly located in the proline-rich region (P-region) (residues 172–251) and the C-terminal tail region (C-region) (residues 368–441) [24]. Tau phosphorylation at both of these regions affects its capacity to interact with microtubules [25]. In terms of AD pathology, the phosphorylation sites located in the C-terminal region seem to cause (a) abnormal folding and (b) protein cleavage, which together could lead to tau deposition [26–28]. Phosphorylation at some sites (Ser262) modifies cell survival as it is known for facilitating a variety of apoptotic mechanisms [35]. Similarly, in an attempt to prevent NMDA-receptor overexcitation (unpublished data).

4. GSK3 as Crucial Node for Synaptic Plasticity

Synaptic plasticity has been proposed to play a central role in brain capacity to incorporate transient experiences into persistent memory traces. Synaptic transmission can be enhanced (long-term potentiation, LTP) or depressed (long-term depression, LTD) by activity, and these changes can persist from seconds to hours and days [39, 40]. Importantly, the affected intracellular pathways leading to LTP or LTD activation involve primarily GSK3 [41, 42]. Indeed, it has been shown that enhanced GSK3 signalling impairs hippocampal memory formation [43]. Specifically, GSK3 activity blocks synaptic LTP and induces LTD [43]. Furthermore, it was found that GSK3 during LTP involves activation of NMDA receptors and the PI3K-Akt pathway consequently disrupting the ability of synapses to undergo LTD [43]. Clearly, the data claims that GSK3 is a crucial node mediating the LTP to LTD transition. Therefore, the simple idea of blocking GSK3 in order to prevent the progression of AD seems to be overly simplistic.

5. Conclusion and Perspectives

The hypothesis that GSK3 plays a role in the aetiology of brain disorders is further nurtured by the fact that several genetic susceptibility factors for psychiatric disorders have key roles in neurodevelopment. Importantly, many of the genes are involved in GSK3 signaling [44, 45]. Furthermore, GSK3 is directly related to the pathogenesis of AD as tau kinase [31]. Overall, it seems clear that GSK3 has an integral role in the pathogenesis of AD. Therefore, GSK3 remains as therapeutic target. However, the secondary effects caused by GSK3 blockade should also be taken into consideration, especially knowing that synaptic dysfunction in addition to neuronal death can lead to cognitive failure associated with AD. With this in mind, therapies that focus on rescuing events like LTP rather than single blocking strategy could bring needed results.

In conclusion, we suggest that downstream targets of GSK3 are an interesting option. In other words, we proposed the use of cocktail drugs that could enhance LTP and reduce induction of LTD. For instance, drugs like memantine (NMDA receptor antagonist) [46], in combination with other drugs like okadaic acid (PP1 activator) [47] and/or pseudosubstrate for Akt [43], could be used in order to balance the activity of GSK3 and therefore tau phosphorylation (Figure 1). Together, this combinatorial approach may result in LTP promotion and synaptic improvement. After all, if the current strategies for AD treatment have shown...
little benefits, it is tempting to consider new therapeutic approaches that are aimed to improve memory formation.

**Abbreviations**

AD: Alzheimer’s disease  
GSK3: Glycogen synthase kinase 3  
NFTs: Neurofibrillary tangles  
LTP: Long-term potentiation  
LTD: Long-term depression  
NMAD: N-methyl-D-aspartate receptor.

**Disclosure**

George Perry is, or has in the past been, a paid consultant for and/or owns equity or stock options in Neurotez Pharmaceuticals, Panacea Pharmaceuticals, Takeda Pharmaceuticals, and Voyager Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the paper apart from those disclosed.

**Acknowledgments**

The authors thank Jesse Jackson for critical comments. Work in the authors’ laboratories is supported by Conacyt, Mexico; Alzheimer’s Association, USA; Alzheimer Society, Canada; CIHR, Canada and FRGQ, Québec, Canada. This project was supported by grants from the National Center for Research Resources (5 G12RR013646-12), the National Institute on Minority Health and Health Disparities (G12MD007591) from the National Institutes of Health, and from the Research Centers in Minority Institutions (RCMI).

**References**


